報價延遲最少15分鐘:2025/04/12 19:42 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.87 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.45/-2.69
|
|
企業價值
346.67M
|
| 資產負債 |
|
每股賬面淨值
-3.71
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 19:42 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies. |